Costantine Albany is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
Sponsor: Costantine Albany
- Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Sponsor: Nabil Adra
- Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
Sponsor: Costantine Albany
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
52 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Tempus AI, IncProgram year20259 payments
- ABBVIE INC.Program year20251 payment
- Astellas Pharma US IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
60.9%RANK Ligand Inhibitor60.5%Denosumab100%Part B, office-administered≥21 patientsXanthine oxidase inhibitor0.5%Allopurinol100%Part D<11 patientsCancer & immunology
13.3%Aromatase Inhibitor5.2%Anastrozole56%Letrozole34%Exemestane10%Part D<11 patientsKinase inhibitor4.4%Calquence27%Ibrance19%Jakafi19%Tagrisso12%Tasigna12%Tafinlar11%Part D<11 patients+ 3 more classes in this area
Blood & clotting
7.3%Factor Xa inhibitor6.7%Eliquis65%Xarelto35%Part D≥33 patientsLow Molecular Weight Heparin0.6%Enoxaparin Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”